Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,067
  • Shares Outstanding, K 24,951
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,940 K
  • 60-Month Beta 3.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.43
  • Low Estimate -0.47
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +12.50%
on 07/07/20
7.45 -52.89%
on 06/29/20
-1.34 (-27.63%)
since 06/12/20
3-Month
3.12 +12.50%
on 07/07/20
7.45 -52.89%
on 06/29/20
-0.43 (-10.91%)
since 04/13/20
52-Week
2.55 +37.65%
on 03/17/20
14.28 -75.42%
on 07/15/19
-10.13 (-74.27%)
since 07/12/19

Most Recent Stories

More News
Regulators Move to Remove Restriction on Some Uses of Psilocybin

, /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway. Earlier this week, an ballot measure to legalize the use of psilocybin, a naturally occurring psychedelic...

APHA : 4.68 (+8.84%)
ZYNE : 3.45 (-7.51%)
MYCOF : 0.5554 (-9.63%)
MYCO.CN : 0.820 (-5.75%)
NVS : 86.08 (-1.07%)
PFE : 35.19 (+4.02%)
APHA.TO : 6.35 (+8.92%)
Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study

Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.

ALDX : 4.70 (-2.49%)
GWPH : 132.19 (+3.35%)
ZYNE : 3.45 (-7.51%)
ATXI : 9.37 (-4.00%)
Thinking about buying stock in YRC Worldwide, Zynerba Pharmaceuticals, Workhorse Group, Vaxart Inc, or United Airlines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for YRCW, ZYNE, WKHS, VXRT, and UAL.

WKHS : 15.65 (+3.10%)
ZYNE : 3.45 (-7.51%)
Thinking about buying stock in Zomedica Pharmaceuticals, Nio Inc, Advanced Micro Devices, Norwegian Cruise Line, or Zynerba Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NIO, AMD, NCLH, and ZYNE.

AMD : 53.65 (-3.99%)
NCLH : 15.60 (-4.88%)
NIO : 13.94 (-6.94%)
ZYNE : 3.45 (-7.51%)
Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel(TM) (CBD Gel) in Fragile X Syndrome

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -

ZYNE : 3.45 (-7.51%)
Implied Volatility Surging For Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

ZYNE : 3.45 (-7.51%)
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba

Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba

GWPH : 132.19 (+3.35%)
ZYNE : 3.45 (-7.51%)
CGC : 17.37 (-0.29%)
ACB : 12.08 (+0.50%)
HEXO : 0.7266 (-3.12%)
Is This a Buying Opportunity in the Marijuana Stocks?

The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?

GWPH : 132.19 (+3.35%)
ZYNE : 3.45 (-7.51%)
CGC : 17.37 (-0.29%)
ACB : 12.08 (+0.50%)
HEXO : 0.7266 (-3.12%)
Therapeutic Use of CBD Continues to Spread

, /PRNewswire/ -- There has been a substantial growth in demand for cannabidiol (CBD) products around the globe in recent years, mainly in developed countries such as the U.S., , and the Netherlands. As...

SRNE : 7.72 (-4.22%)
VFF : 5.00 (-1.96%)
WBA : 39.62 (-1.25%)
TAAT.CN : 0.920 (+10.84%)
ZYNE : 3.45 (-7.51%)
VFF.TO : 6.78 (-1.88%)
Psychedelics Represent a New Frontier for Mental Healthcare

, /PRNewswire/ -- Despite the various stigmas associated with psychedelics, there is a growing acceptance of using psychedelic drugs specifically to treat depression. Such drugs have regularly proven...

IIPR : 89.34 (-1.59%)
NLBIF : 0.6150 (-6.82%)
MYCO.CN : 0.820 (-5.75%)
ZYNE : 3.45 (-7.51%)
APHA : 4.68 (+8.84%)
CGC : 17.37 (-0.29%)
WEED.TO : 23.64 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 4.04
1st Resistance Point 3.89
Last Price 3.45
1st Support Level 3.49
2nd Support Level 3.24

See More

52-Week High 14.28
Fibonacci 61.8% 9.80
Fibonacci 50% 8.41
Fibonacci 38.2% 7.03
Last Price 3.45
52-Week Low 2.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar